Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease
Miloš D. Miljković(Tufts University), Metin Kurtoğlu, Nizar Chahin(Oregon Health & Science University), James F. Howard(University of North Carolina at Chapel Hill), Gregory Orloff(Virginia Cancer Specialists), Jesús G. Berdeja(Tennessee Oncology), Christopher M. Jewell(University of Maryland, Baltimore), Tahseen Mozaffar(University of North Carolina at Chapel Hill), Stefan O. Ciurea(University of California, Irvine), Bennett Myers(Dent Neurologic Institute), Adam S. Asch(Cornell University), Fevzi Altuntaş, Ralph V. Boccia(Center for Cancer and Blood Disorders), Tuan Vu(University of South Florida)
Cited by 6
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695